ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2020
Hazard of Cervical, Oropharyngeal, and Anal Cancers in HIV-Infected and HIV-Uninfected Medicaid Beneficiaries.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Oropharyngeal cancer risk groups in the United States: a meta-analysis and SEER analysis.BMC cancer · 2025Pooled it
- Sex and organ-specific risk and temporal trends of human papillomavirus-associated anogenital cancer among solid organ transplant recipients in the United States.International journal of cancer · 2026Article
- Review
- Leveraging Electronic Health Records and Claims Data to Improve HIV and Comorbidity Care Trajectories: A Scoping Review.Current HIV/AIDS reports · 2025Article
- Anal cancer impact among people with HIV infection - a matched cohort study.Ecancermedicalscience · 2025Article
- Characteristics of HPV Infection in Women Cervical and Anal with HIV-Infected and the Advances in Epidemiological Research.Infection and drug resistance · 2025Review
- Follow-Up Time of Anal Cancer Screening among Women Living with HIV at High Risk of Developing Anal Cancer.Oncology research and treatment · 2025Article
- Challenges and opportunities in monitoring the long-term well-being of people with HIV in Spain.PloS one · 2025Article
- Anal cancer screening among women with HIV: provider experiences and system-level challenges.AIDS care · 2022Article
- Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV.Nature communications · 2021Review
- A comparison of screening tests for detection of high-grade cervical abnormalities in women living with HIV from Cameroon.Infectious agents and cancer · 2020Article
- Cancer burden in women with HIV on Medicaid: A nationwide analysis.Women's health (London, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundHuman immunodeficiency virus-infected (HIV
methodsUsing 2001-2012 U.S. Medicaid data from 14 states, we matched one HIV
resultsOur cohorts included 443,592 women for the cervical cancer analysis, and 907,348 and 906,616 persons for the oropharyngeal and anal cancer analyses. The cervical cancer cohort had a mean age of 39 years and was 55% Black. The oropharyngeal and anal cancer cohorts were 50% male, had a mean age of 41 years, and were 51% Black. We estimated the following HRs: cervical cancer, 3.27 [95% confidence interval (CI), 2.82-3.80]; oropharyngeal cancer, 1.90 (95% CI, 1.62-2.23; both sexes), 1.69 (95% CI, 1.39-2.04; males), and 2.55 (95% CI, 1.86-3.50; females); and anal cancer, 18.42 (95% CI, 14.65-23.16; both sexes), 20.73 (95% CI, 15.60-27.56; males), and 12.88 (95% CI, 8.69-19.07; females).
conclusionsHIV IMPACT: Medicaid claims data corroborate previous estimates based on registries and clinical cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.